Therapeutic Fasting and Caloric Restriction in Oncology

Emerging evidence for fasting-mimicking diets to enhance chemotherapy efficacy and reduce toxicity

Key Points

• Short-term fasting (24–72 h) before and after chemotherapy may reduce toxicity in normal cells via "differential stress resistance" — cancer cells cannot downregulate growth signaling, while normal cells enter a cytoprotective state.
• The DIRECT trial (Leiden University, 2023) showed that a Fasting Mimicking Diet (FMD) around each chemotherapy cycle improved objective tumor response and pathological complete response rates in HER2-negative breast cancer.
• FMD cycles (5 days, ~600–800 kcal/day of plant-based, low-protein, low-sugar food) are better tolerated than water-only fasting while maintaining the metabolic fasting state.
• Caution required in patients with malnutrition, cachexia, diabetes, or who are underweight — fasting is contraindicated in these populations.
• Activates autophagy, reduces IGF-1 and insulin levels, and sensitizes tumor cells to chemotherapy-induced DNA damage.
• Not yet standard of care — patient selection, optimal fasting duration, and interaction with specific chemotherapy agents require further study.

Scientific Rationale

The scientific basis for fasting in oncology derives from fundamental differences between normal cell and cancer cell responses to nutrient deprivation — a concept formalized by Longo et al. as "differential stress resistance" (DSR). Normal cells, when deprived of nutrients, activate pro-survival pathways: downregulating IGF-1/mTOR/PI3K growth signaling, entering a quiescent, resource-conserving state, activating autophagy for cellular recycling, and upregulating antioxidant defenses. This creates resilience against chemotherapy toxicity — because many chemotherapeutic agents kill rapidly…

Clinical Evidence

**DIRECT Trial (NCT02126449):** This Dutch Phase II RCT (de Groot et al., Nature Commun 2020; extended results 2023) enrolled 131 women with HER2-negative breast cancer receiving neoadjuvant or adjuvant chemotherapy (AC or AC-T). Patients randomized to FMD (fasting-mimicking diet cycles of 5 days around each chemotherapy cycle) vs. unrestricted diet showed: - Significantly higher objective radiological response rates (80% vs. 59%) - Trend toward higher pathological complete response (pCR) - No increase in chemotherapy toxicity - No significant weight loss or nutritional compromise in the FMD…

Fasting Mimicking Diet Protocol

The Fasting Mimicking Diet (FMD) was developed by the Longo laboratory at USC and commercialized as ProLon (L-Nutra). It provides ~600–800 kcal/day over 5 consecutive days with specific macronutrient ratios: - Day 1: ~1,100 kcal (10% protein, 56% fat, 34% carbohydrate) - Days 2–5: ~700 kcal (9% protein, 44% fat, 47% carbohydrate) - Composition: plant-based soups, bars, teas, kale crackers, glycerol supplements; no animal products; very low protein (minimizes mTOR activation) In oncology clinical trials, FMD is typically prescribed for 5 days beginning 2 days before chemotherapy infusion and…